Amylyx Pharmaceuticals Inc (AMLX)vsTeva Pharma Industries Ltd ADR (TEVA)
AMLX
Amylyx Pharmaceuticals Inc
$14.73
-3.09%
HEALTHCARE · Cap: $1.69B
TEVA
Teva Pharma Industries Ltd ADR
$35.73
-0.78%
HEALTHCARE · Cap: $41.93B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates -2608972% more annual revenue ($17.35B vs $-665,000). TEVA leads profitability with a 9.0% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 62/100 (C+).
AMLX
Avoid31
out of 100
Grade: F
TEVA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AMLX.
Margin of Safety
+46.3%
Fair Value
$63.92
Current Price
$35.73
$28.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 72.2% YoY
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
AMLX has a balanced fundamental profile.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, Return on Equity.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Market Cap, Profit Margin.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.86 — expect wider price swings.
TEVA is growing revenue faster at 2.3% — sustainability is the question.
AMLX generates stronger free cash flow (-37M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (62/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating innovative therapies for neurodegenerative conditions, with a strong emphasis on amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, showcases a novel neuroprotective mechanism that aims to significantly improve patient outcomes, representing a promising advancement in ALS treatment. With a solid clinical development pipeline and a deep expertise in the nuances of neurological disorders, Amylyx is strategically positioned to address urgent unmet medical needs in ALS and potentially other related diseases, making it a compelling prospect for institutional investors.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?